Bioprofarma Bagó was present on October 24th and 25th at the Uro-Oncology Conference: Controversies and New Developments 2024, organized by the FUCDIM Urology Center in the city of Córdoba.
The conference discussions focused on:
- High-risk and locally advanced prostate cancer
- Non-muscle-invasive bladder cancer (NMIBC)
Our representative, Mariano Nalbandian, led the promotion and communication of our CarciVac® product, indicated for NMIBC, along with UroControl®, a diagnostic test for the early detection of NMIBC.
He also continued presenting our latest product launch, HUTUS® enzalutamide, to the medical community, along with the portfolio of other products that make up our Uro-Oncology line.
24 October, 2024
Bioprofarma Bagó
Trabajando el presente, pensando el futuro.
Noticias relacionadas
Bioprofarma Bagó Announces In-Licensing Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20
Buenos Aires, Argentina – Bioprofarma Bagó (a fully owned subsidiary of GRUPO...
14 December, 2025
New release LIPECELTE® trabectedin
Introducing LIPECELTE® Trabectedin: A New Addition to Our Oncology Line At Bioprofarma Bagó, we reaffirm our...
23 December, 2024